Jefferies raised the firm’s price target on AxoGen (AXGN) to $29 from $25 and keeps a Buy rating on the shares after Q3 sales beat consensus by about 6% and the company raised FY25 sales growth guidance to at least 19% year-over-year. The Q3 report “showed solid execution all around,” the analyst tells investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXGN: